trial_id
stringlengths 11
11
| question
stringlengths 154
5.24k
| options
dict | answer
stringclasses 4
values | trials
listlengths 4
4
| id
int64 0
27.3k
| split
stringclasses 2
values |
|---|---|---|---|---|---|---|
NCT00027300
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
|
{
"A": "Arm Label: OMG 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMG 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg",
"B": "Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM",
"C": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"D": "Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab"
}
|
C
|
[
"NCT02792231",
"NCT01064401",
"NCT00027300",
"NCT01144052"
] | 400 |
train
|
NCT00027300
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
|
{
"A": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"B": "Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo",
"C": "Arm Label: Alemtuzumab 12 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 12 mg | Arm Label: Alemtuzumab 24 mg; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab 24 mg | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 12 mg; Assigned to Arm(s): Alemtuzumab 12 mg | Intervention Type: BIOLOGICAL; Name: Alemtuzumab 24 mg; Assigned to Arm(s): Alemtuzumab 24 mg | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a",
"D": "Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)"
}
|
A
|
[
"NCT00027300",
"NCT00134563",
"NCT00548405",
"NCT00333138"
] | 401 |
train
|
NCT00027300
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
|
{
"A": "Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo",
"B": "Arm Label: GTR; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (GTR) | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate (Copaxone®) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate (GTR); Assigned to Arm(s): GTR | Intervention Type: DRUG; Name: Glatiramer Acetate (Copaxone®); Assigned to Arm(s): Copaxone® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: BAF312 10mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 2 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 0.5 mg (period 1); Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 to 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: BAF312 dose between 0.1 - 8 mg period 2; Type: EXPERIMENTAL; Interventions: Drug: BAF312 | Arm Label: Placebo (period 1, 2); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BAF312; Assigned to Arm(s): BAF312 0.5 mg (period 1), BAF312 10mg (period 1), BAF312 2 mg (period 1), BAF312 dose between 0.1 - 8 mg period 2, BAF312 dose between 0.1 to 8 mg period 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (period 1, 2)",
"D": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2"
}
|
D
|
[
"NCT00134563",
"NCT01489254",
"NCT00879658",
"NCT00027300"
] | 402 |
train
|
NCT00027300
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in the treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis (MS). It is hoped that natalizumab will prevent certain types of white blood cells from moving out of the bloodstream into organs, including the brain, that are being damaged by autoimmune disease (a disease in which the body's own immune system attacks certain organs). These white blood cells are thought to cause inflammation that can result in lesions (small areas of damage) in the brain. These lesions are thought to be the cause of relapses and disability in MS.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon-beta-1a (Avonex) plus methylprednisolone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Interferon-beta-1a (Avonex) plus methylprednisolone | Intervention Type: DRUG; Name: Interferon-beta-1a (Avonex) plus methylprednisolone; Assigned to Arm(s): 1, 2",
"B": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"C": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"D": "Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®"
}
|
C
|
[
"NCT00168766",
"NCT00030966",
"NCT00027300",
"NCT00078338"
] | 403 |
train
|
NCT00027352
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy (The SMART Study)
Brief Summary: The purpose of this study is to compare two ways of using anti-HIV drugs to help health care providers and patients decide how to best use anti-HIV treatments over many years. Many health care providers now treat patients with daily drugs to keep the viral load as low as possible. This approach helps patients with CD4 counts less than 200-250 cells/mm3 live longer without serious diseases. But it is not known if this is the best way to treat patients with higher CD4 counts. There is information suggesting that these patients may be able to wait to use anti-HIV drugs while CD4 counts are above 250 cells/mm3. Because this study will be carried out over several years, it will provide information on the long-term advantages and disadvantages of these two treatment strategies.
|
{
"A": "N/A",
"B": "Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Standard Care + Text message; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Text Message | Arm Label: Standard Care + Text Message + ABT; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Text Message, Behavioral: Adherence Behavioral Therapy | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Standard Care, Standard Care + Text Message + ABT, Standard Care + Text message | Intervention Type: BEHAVIORAL; Name: Text Message; Assigned to Arm(s): Standard Care + Text Message + ABT, Standard Care + Text message | Intervention Type: BEHAVIORAL; Name: Adherence Behavioral Therapy; Assigned to Arm(s): Standard Care + Text Message + ABT",
"C": "Arm Label: Intensive behavioral intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Positively Smoke Free | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Positively Smoke Free; Assigned to Arm(s): Intensive behavioral intervention | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard care",
"D": "Arm Label: Standard Care; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care | Arm Label: Motivational Enhancement; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Enhancement | Intervention Type: BEHAVIORAL; Name: Standard Care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement; Assigned to Arm(s): Motivational Enhancement"
}
|
A
|
[
"NCT00027352",
"NCT01898195",
"NCT01106638",
"NCT00551720"
] | 404 |
train
|
NCT00027378
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Intervention Project (Fluoxetine)
Brief Summary: This is a large scale study involving fluoxetine (Prozac) versus a placebo in the treatment of adolescents with alcohol use disorder (AUD) and major depression (MDD). All individuals will receive treatment for 12 weeks with a followup phase lasting 9 months.
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2",
"C": "Arm Label: Desvenlafaxine Succinate Sustained-Release; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): Desvenlafaxine Succinate Sustained-Release",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: Duloxetine 60 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: Duloxetine 30 mg; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): Duloxetine 30 mg"
}
|
B
|
[
"NCT00849901",
"NCT00027378",
"NCT01371721",
"NCT00849693"
] | 405 |
train
|
NCT00027378
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacological Intervention Project (Fluoxetine)
Brief Summary: This is a large scale study involving fluoxetine (Prozac) versus a placebo in the treatment of adolescents with alcohol use disorder (AUD) and major depression (MDD). All individuals will receive treatment for 12 weeks with a followup phase lasting 9 months.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: fluoxetine (Prozac) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus Treatment As Usual | Intervention Type: DRUG; Name: fluoxetine (Prozac); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo plus Treatment As Usual; Assigned to Arm(s): 2",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Multifamily Psychoeducation Group (MFPG), Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Multifamily Psychoeducation Group (MFPG); Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): 1, 2",
"C": "Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Psychotherapy; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Behavioral: Cognitive Behavioral Therapy (CBT), Drug: Citalopram | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Venlafaxine, Behavioral: Cognitive Behavioral Therapy (CBT) | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): 2, 4 | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): 3, 4 | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): 1, 3"
}
|
A
|
[
"NCT00027378",
"NCT00050557",
"NCT00006286",
"NCT00018902"
] | 406 |
train
|
NCT00027963
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy Of Gabapentin In The Management Of Chemotherapy-Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
Brief Summary: RATIONALE: Gabapentin may be effective in relieving pain and other symptoms of peripheral neuropathy. It is not yet known if gabapentin is effective in treating peripheral neuropathy in cancer patients undergoing chemotherapy.
PURPOSE: Randomized phase III trial to determine the effectiveness of gabapentin in treating pain and other symptoms of peripheral neuropathy in cancer patients undergoing chemotherapy.
|
{
"A": "Arm Label: gabapentin; Type: EXPERIMENTAL; Interventions: Drug: gabapentin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): gabapentin | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo",
"B": "Arm Label: Sham-laser acupuncture; Type: SHAM_COMPARATOR; Interventions: Device: Sham-laser acupuncture | Arm Label: gabapentine; Type: ACTIVE_COMPARATOR; Interventions: Drug: gabapentine | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Acupuncture | Intervention Type: DEVICE; Name: Sham-laser acupuncture; Assigned to Arm(s): Sham-laser acupuncture | Intervention Type: DRUG; Name: gabapentine; Assigned to Arm(s): gabapentine | Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): Acupuncture",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin Extended Release tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin Extended Release tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2",
"D": "Arm Label: Open Label; Type: N/A; Interventions: N/A | Arm Label: Open label; Type: N/A; Interventions: N/A"
}
|
A
|
[
"NCT00027963",
"NCT00885586",
"NCT00712439",
"NCT01426230"
] | 407 |
train
|
NCT00028288
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma
Brief Summary: The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
|
{
"A": "Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: lebrikizumab (MILR1444A) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: lebrikizumab (MILR1444A); Assigned to Arm(s): A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): B",
"C": "Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A",
"D": "Arm Label: Benralizumab (Medi-563); Type: EXPERIMENTAL; Interventions: Drug: Benralizumab (Medi-563) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab (Medi-563); Assigned to Arm(s): Benralizumab (Medi-563) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT00974675",
"NCT00781443",
"NCT00028288",
"NCT03170271"
] | 408 |
train
|
NCT00028288
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma
Brief Summary: The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to 70 years old. Participants in the study will have a number of visits to a research site over a 10-month period. All study-related care and medication is provided to qualified participants at no cost: this includes all visits, examinations and laboratory work.
|
{
"A": "Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab 0.3 mg/kg, Benralizumab 1.0 mg/kg",
"D": "Intervention Type: DRUG; Name: Daclizumab; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00207740",
"NCT01508936",
"NCT00768079",
"NCT00028288"
] | 409 |
train
|
NCT00028990
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Tial Of Paclitaxel Versus Paclitaxel Plus Bevacizumab (rhuMAb VEGF) As First-Line Therapy For Locally Recurrent or Metastatic Breast Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known whether paclitaxel works better with or without bevacizumab in treating breast cancer.
PURPOSE: This randomized phase III trial is to see if paclitaxel works better with or without bevacizumab in treating patients who have locally recurrent or metastatic breast cancer.
|
{
"A": "Arm Label: Bevacizumab for ROP; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: Conventional Laser for ROP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Laser for ROP | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab for ROP | Intervention Type: PROCEDURE; Name: Conventional Laser for ROP; Assigned to Arm(s): Conventional Laser for ROP",
"B": "Intervention Type: DRUG; Name: rhuFab V2 (ranibizumab); Assigned to Arm(s): N/A",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: ranibizumab | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: ranibizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: bevacizumab | Intervention Type: DRUG; Name: ranibizumab; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): 2, 4",
"D": "Arm Label: Paclitaxel + Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, Drug: Paclitaxel | Arm Label: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Paclitaxel + Bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel, Paclitaxel + Bevacizumab"
}
|
D
|
[
"NCT00622726",
"NCT00056836",
"NCT00593450",
"NCT00028990"
] | 410 |
train
|
NCT00029770
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic Care, Medication, and Self-Care for Neck Pain
Brief Summary: This study will compare the effectiveness of chiropractic care, medications, and self-care on neck pain, a very common condition. The broad, long-term objective of this study is to identify effective therapies for neck pain sufferers and to increase understanding of neck pain conditions.
|
{
"A": "Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A",
"B": "Arm Label: 9 months of chiropractic care and exercise; Type: EXPERIMENTAL; Interventions: Other: chiropractic, Behavioral: exercise | Arm Label: 3 months of chiropractic care and exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: chiropractic, Behavioral: exercise | Intervention Type: OTHER; Name: chiropractic; Assigned to Arm(s): 3 months of chiropractic care and exercise, 9 months of chiropractic care and exercise | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 3 months of chiropractic care and exercise, 9 months of chiropractic care and exercise",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Chiropractic Manual treatment + home exercise ( procedure+behavior) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Supervised rehabilitative exercise + home exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home exercise | Intervention Type: PROCEDURE; Name: Chiropractic Manual treatment + home exercise ( procedure+behavior); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Supervised rehabilitative exercise + home exercise; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Home exercise; Assigned to Arm(s): 3",
"D": "Intervention Type: PROCEDURE; Name: Usual Care provided by a medical doctor (GP or Neurologist); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Usual care plus Physio-/ Manual Therapy; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00029770",
"NCT01057706",
"NCT00269308",
"NCT00298142"
] | 411 |
train
|
NCT00029770
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic Care, Medication, and Self-Care for Neck Pain
Brief Summary: This study will compare the effectiveness of chiropractic care, medications, and self-care on neck pain, a very common condition. The broad, long-term objective of this study is to identify effective therapies for neck pain sufferers and to increase understanding of neck pain conditions.
|
{
"A": "Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A",
"B": "Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program",
"C": "Arm Label: Specific resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck; Assigned to Arm(s): Specific resistance training",
"D": "Intervention Type: BEHAVIORAL; Name: Behavioral treatments; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Physical therapy; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00029770",
"NCT00551980",
"NCT01071980",
"NCT00021476"
] | 412 |
train
|
NCT00029770
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic Care, Medication, and Self-Care for Neck Pain
Brief Summary: This study will compare the effectiveness of chiropractic care, medications, and self-care on neck pain, a very common condition. The broad, long-term objective of this study is to identify effective therapies for neck pain sufferers and to increase understanding of neck pain conditions.
|
{
"A": "Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A",
"B": "Arm Label: 1 hr training 50% supervision; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: 3 x 20 min training 50% supervision; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: 3 x 20 min training initial instructions; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: 10 x 6 min training 50% supervision; Type: EXPERIMENTAL; Interventions: Behavioral: physical training exercise | Arm Label: reference; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: physical training exercise; Assigned to Arm(s): 1 hr training 50% supervision, 10 x 6 min training 50% supervision, 3 x 20 min training 50% supervision, 3 x 20 min training initial instructions",
"C": "Arm Label: Cognitive and physical program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive, Relaxation, Exercise Therapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive, Relaxation, Exercise Therapy; Assigned to Arm(s): Cognitive and physical program",
"D": "Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal manipulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Spinal manipulation + exercises | Intervention Type: OTHER; Name: spinal manipulation; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Spinal manipulation + exercises; Assigned to Arm(s): 3"
}
|
A
|
[
"NCT00029770",
"NCT01027390",
"NCT00551980",
"NCT00566930"
] | 413 |
train
|
NCT00029848
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing Effect and Safety in Obese Patients With Type 2 Diabetes
Brief Summary: To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes
|
{
"A": "Arm Label: Lorcaserin 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin 10 mg BID | Arm Label: Matching Placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching Placebo BID | Intervention Type: DRUG; Name: Lorcaserin 10 mg BID; Assigned to Arm(s): Lorcaserin 10 mg BID | Intervention Type: DRUG; Name: Matching Placebo BID; Assigned to Arm(s): Matching Placebo BID",
"B": "Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: NB32, Behavioral: Weight Management Program | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PBO, Behavioral: Weight Management Program | Intervention Type: DRUG; Name: NB32; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): PBO | Intervention Type: BEHAVIORAL; Name: Weight Management Program; Assigned to Arm(s): NB32, PBO",
"C": "Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A",
"D": "Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide"
}
|
C
|
[
"NCT00395135",
"NCT01601704",
"NCT00029848",
"NCT01499108"
] | 414 |
train
|
NCT00029861
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities
Brief Summary: To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities
|
{
"A": "Arm Label: Rimonabant; Type: EXPERIMENTAL; Interventions: Drug: Rimonabant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Rimonabant) | Intervention Type: DRUG; Name: Rimonabant; Assigned to Arm(s): Rimonabant | Intervention Type: DRUG; Name: Placebo (for Rimonabant); Assigned to Arm(s): Placebo",
"B": "Arm Label: Lorcaserin hydrochloride (HCL)10 mg; Type: EXPERIMENTAL; Interventions: Drug: Lorcaserin hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin hydrochloride; Assigned to Arm(s): Lorcaserin hydrochloride (HCL)10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: VI-0521 Mid; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Arm Label: VI-0521 Top; Type: EXPERIMENTAL; Interventions: Drug: VI-0521 | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Mid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VI-0521; Assigned to Arm(s): VI-0521 Top",
"D": "Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00228176",
"NCT02019264",
"NCT00796367",
"NCT00029861"
] | 415 |
train
|
NCT00030966
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
|
{
"A": "Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)",
"C": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"D": "Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM"
}
|
C
|
[
"NCT01416181",
"NCT01216072",
"NCT00030966",
"NCT01064401"
] | 416 |
train
|
NCT00030966
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: 300 mg DAC HYP; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): 150 mg DAC HYP, 300 mg DAC HYP | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Ocrelizumab 600 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Ocrelizumab 1000 mg; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab | Arm Label: Avonex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Avonex | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 1000 mg, Ocrelizumab 600 mg | Intervention Type: DRUG; Name: Avonex; Assigned to Arm(s): Avonex",
"D": "Arm Label: Atacicept 25 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 25 mg | Arm Label: Atacicept 75 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 75 mg | Arm Label: Atacicept 150 mg (With Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 150 mg | Arm Label: Atacicept 150 mg (Without Loading); Type: EXPERIMENTAL; Interventions: Drug: Atacicept 150 mg | Intervention Type: DRUG; Name: Atacicept 25 mg; Assigned to Arm(s): Atacicept 25 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 75 mg; Assigned to Arm(s): Atacicept 75 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 150 mg; Assigned to Arm(s): Atacicept 150 mg (With Loading) | Intervention Type: DRUG; Name: Atacicept 150 mg; Assigned to Arm(s): Atacicept 150 mg (Without Loading)"
}
|
B
|
[
"NCT00390221",
"NCT00030966",
"NCT00676715",
"NCT00853762"
] | 417 |
train
|
NCT00030966
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
|
{
"A": "Arm Label: Group 1: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 1: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 2: Washout then DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 2: DAC HYP 150 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Arm Label: Group 3: Washout then DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Placebo | Arm Label: Group 3: DAC HYP 300 mg; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process) | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Group 1: DAC HYP 150 mg, Group 1: DAC HYP 300 mg, Group 2: DAC HYP 150 mg, Group 2: Washout then DAC HYP 150 mg, Group 3: DAC HYP 300 mg, Group 3: Washout then DAC HYP 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Washout then DAC HYP 150 mg, Group 3: Washout then DAC HYP 300 mg",
"B": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"C": "Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab",
"D": "Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM"
}
|
B
|
[
"NCT00870740",
"NCT00030966",
"NCT01144052",
"NCT01064401"
] | 418 |
train
|
NCT00030966
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Natalizumab, When Added to Avonex® (Interferon Beta-1a), in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The purpose of this study is to determine if natalizumab in combination with AVONEX is safe and effective in delaying progression of individuals diagnosed with relapsing remitting Multiple Sclerosis (MS).
|
{
"A": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"B": "Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®",
"C": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"D": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3"
}
|
C
|
[
"NCT00027300",
"NCT00078338",
"NCT00030966",
"NCT00099502"
] | 419 |
train
|
NCT00031395
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)
Brief Summary: The purpose of this study is to determine the safety and efficacy of clonidine alone or in combination with methylphenidate for children 7-12 years of age with attention-deficit, hyperactivity disorder.
|
{
"A": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine, Drug: methylphenidate | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: clonidine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 4",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate",
"C": "Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta",
"D": "Arm Label: ADHD; Type: N/A; Interventions: N/A"
}
|
A
|
[
"NCT00031395",
"NCT01238822",
"NCT00444574",
"NCT01252446"
] | 420 |
train
|
NCT00031395
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) Treatment (CAT)
Brief Summary: The purpose of this study is to determine the safety and efficacy of clonidine alone or in combination with methylphenidate for children 7-12 years of age with attention-deficit, hyperactivity disorder.
|
{
"A": "Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR); Assigned to Arm(s): Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg, Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Pain medication: diclofenac and atropine; Type: EXPERIMENTAL; Interventions: Drug: Diclofenac and Atropine combination drug | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Diclofenac and Atropine combination drug; Assigned to Arm(s): Pain medication: diclofenac and atropine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo",
"C": "Arm Label: Active drug group; Type: EXPERIMENTAL; Interventions: Drug: Drug: PRC-063, Drug: PRC-063 | Intervention Type: DRUG; Name: Drug: PRC-063; Assigned to Arm(s): Active drug group | Intervention Type: DRUG; Name: PRC-063; Assigned to Arm(s): Active drug group",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine, Drug: methylphenidate | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: clonidine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 4"
}
|
D
|
[
"NCT00776009",
"NCT02194088",
"NCT02168127",
"NCT00031395"
] | 421 |
train
|
NCT00031499
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Equivalence Trial of Azithromycin vs. Benzathine Penicillin for the Treatment of Early Syphilis
Brief Summary: The purpose of this study is to determine if azithromycin, a drug approved for treatment of other infections, is as effective for syphilis (a sexually transmitted disease) as the standard treatment. Approximately 600 healthy adults, who are HIV-negative, ages 18 to 55 years of age, with primary, secondary or early latent syphilis, will participate in this research study. Volunteers will be enrolled in 5 U.S. cities and in Madagascar. Participants will be chosen randomly (by chance) to receive 1 of 2 study drugs: benzathine penicillin given (2 shots in the buttocks) or 4 tablets of azithromycin. Subjects who report a history of a penicillin allergy will be given either 2.0 g of oral azithromycin or 100 mg doxycycline taken orally, twice a day for 14 days. Over 2 years, 10 visits will be required. Procedures will include blood samples, physical exams, and swabs of sores.
|
{
"A": "Intervention Type: DRUG; Name: acyclovir; Assigned to Arm(s): N/A",
"B": "Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Benzathine Penicillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Benzathine Penicillin, Drug: Doxycycline | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Benzathine Penicillin; Assigned to Arm(s): Benzathine Penicillin | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Benzathine Penicillin",
"C": "Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Valacyclovir, Drug: Matching Placebo | Intervention Type: DRUG; Name: Valacyclovir; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Matching Placebo; Assigned to Arm(s): I",
"D": "Intervention Type: DRUG; Name: Acyclovir (ACV); Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00362596",
"NCT00031499",
"NCT00465205",
"NCT00158483"
] | 422 |
train
|
NCT00032227
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Carpal Tunnel Syndrome: Diagnosis and Treatment Trial
Brief Summary: The Carpal Tunnel Syndrome Diagnosis and Treatment Trial is project #1 of the Multidisciplinary Clinical Research Center focused on upper extremity pain. It is a randomized trial comparing surgical and nonsurgical treatments for patients with early, mild to moderate carpal tunnel syndrome. In addition the study will evaluate the ability of a new magnetic resonance (MR) technique at predicting who will likely benefit from carpal tunnel syndrome (CTS) surgery.
|
{
"A": "Arm Label: Conservative group; Type: EXPERIMENTAL; Interventions: Other: Conservative group | Arm Label: Surgical group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical group | Intervention Type: OTHER; Name: Conservative group; Assigned to Arm(s): Conservative group | Intervention Type: PROCEDURE; Name: Surgical group; Assigned to Arm(s): Surgical group",
"B": "Arm Label: Methylprednisolone 80 mg; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone 80 mg | Arm Label: Methylprednisolone 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone 40 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline | Intervention Type: DRUG; Name: Methylprednisolone 80 mg; Assigned to Arm(s): Methylprednisolone 80 mg | Intervention Type: DRUG; Name: Methylprednisolone 40 mg; Assigned to Arm(s): Methylprednisolone 40 mg | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Placebo",
"C": "Arm Label: Physical Therapy Group.; Type: EXPERIMENTAL; Interventions: Other: Physical Therapy Group | Arm Label: Surgical Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical Group | Intervention Type: OTHER; Name: Physical Therapy Group; Assigned to Arm(s): Physical Therapy Group. | Intervention Type: PROCEDURE; Name: Surgical Group; Assigned to Arm(s): Surgical Group",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Early Carpal Tunnel Release for Mild or Moderate CTS, Other: MR Nerve Imaging for CTS | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Early Carpal Tunnel Release for Mild or Moderate CTS, Other: MR Nerve Imaging for CTS | Intervention Type: PROCEDURE; Name: Early Carpal Tunnel Release for Mild or Moderate CTS; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: MR Nerve Imaging for CTS; Assigned to Arm(s): 1, 2"
}
|
D
|
[
"NCT01789645",
"NCT02652390",
"NCT02233660",
"NCT00032227"
] | 423 |
train
|
NCT00032240
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial of a Wedged Insole for Treatment of Osteoarthritis of the Knee
Brief Summary: This trial will test shoe inserts for the treatment of knee osteoarthritis, the most common form of knee arthritis. Those with disease on the inner (medial) aspect of the knee will be studied.
|
{
"A": "Arm Label: Shortwave diathermy; Type: EXPERIMENTAL; Interventions: Device: Shortwave diathermy | Arm Label: control; Type: SHAM_COMPARATOR; Interventions: Device: Shortwave diathermy | Intervention Type: DEVICE; Name: Shortwave diathermy; Assigned to Arm(s): Shortwave diathermy, control",
"B": "Arm Label: Kinesio taping group; Type: EXPERIMENTAL; Interventions: Other: Taping application | Arm Label: Non specific taping; Type: SHAM_COMPARATOR; Interventions: Other: Taping application | Intervention Type: OTHER; Name: Taping application; Assigned to Arm(s): Kinesio taping group, Non specific taping",
"C": "Intervention Type: DEVICE; Name: Shoe Insert; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: thermal cure | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Drug: 3 days access to watering place at 6 months | Intervention Type: DRUG; Name: thermal cure; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 3 days access to watering place at 6 months; Assigned to Arm(s): 2"
}
|
C
|
[
"NCT00199914",
"NCT03076177",
"NCT00032240",
"NCT00348777"
] | 424 |
train
|
NCT00032435
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)
Brief Summary: The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
|
{
"A": "Intervention Type: PROCEDURE; Name: consumption of fortified bread; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Folate; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00353353",
"NCT00032435",
"NCT00106886",
"NCT00272324"
] | 425 |
train
|
NCT00032435
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)
Brief Summary: The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
|
{
"A": "Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2",
"C": "Arm Label: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug); Type: ACTIVE_COMPARATOR; Interventions: Drug: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo | Arm Label: Placebo Tablet; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) or placebo; Assigned to Arm(s): Active VITATOPS Tablet (folic acid 2mg, B6 25mg , B12 500ug) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Tablet",
"D": "Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00384618",
"NCT00032435",
"NCT00097669",
"NCT00106886"
] | 426 |
train
|
NCT00032435
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #453 - Homocysteinemia in Kidney and Endstage Renal Disease Study (HOST)
Brief Summary: The primary objective of this study is to test the hypothesis that administration of folate, pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) in high doses to patients with advanced chronic renal failure or end stage renal disease and abnormally high plasma homocysteine levels will lower the homocysteine levels and the death rate compared to patients who receive placebo. The secondary objective is to test the hypothesis that intake of the vitamins compared to placebo decreases the incidence of myocardial infarction, disabling stroke, and amputation of a lower extremity and, in hemodialysis patients, thrombosis of the vascular access.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: PAL-40 Active | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: PAL-40 Placebo | Intervention Type: DRUG; Name: PAL-40 Active; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: PAL-40 Placebo; Assigned to Arm(s): 2",
"C": "Intervention Type: DRUG; Name: Folic acid, vitamin B6 and B12 or placebo; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Folic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B12; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin B6; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00000541",
"NCT00032435",
"NCT00106886",
"NCT00266487"
] | 427 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: DVS SR Open Label; Type: OTHER; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): DVS SR Open Label",
"B": "Arm Label: Revascularization and Insulin Providing (IP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Procedure: Coronary Artery Bypass, Drug: Insulin, sulfonylurea, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Revascularization and Insulin Sensitizing (IS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Procedure: Coronary Artery Bypass, Drug: Biguanides, thiazolidinediones, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Medical Therapy and Insulin Providing (IP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, sulfonylurea, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Medical Therapy and Insulin Sensitizing (IS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Biguanides, thiazolidinediones, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Intervention Type: PROCEDURE; Name: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions; Assigned to Arm(s): Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS) | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass; Assigned to Arm(s): Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS) | Intervention Type: DRUG; Name: Biguanides, thiazolidinediones; Assigned to Arm(s): Medical Therapy and Insulin Sensitizing (IS), Revascularization and Insulin Sensitizing (IS) | Intervention Type: DRUG; Name: Insulin, sulfonylurea; Assigned to Arm(s): Medical Therapy and Insulin Providing (IP), Revascularization and Insulin Providing (IP) | Intervention Type: DRUG; Name: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers; Assigned to Arm(s): Medical Therapy and Insulin Providing (IP), Medical Therapy and Insulin Sensitizing (IS), Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS)",
"C": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"D": "Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 50mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 100mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 200mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: desvenlafaxine succinate sustained-release (DVS SR) 400mg; Type: EXPERIMENTAL; Interventions: Drug: DVS SR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DVS SR; Assigned to Arm(s): desvenlafaxine succinate sustained-release (DVS SR) 100mg, desvenlafaxine succinate sustained-release (DVS SR) 200mg, desvenlafaxine succinate sustained-release (DVS SR) 400mg, desvenlafaxine succinate sustained-release (DVS SR) 50mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT01050218",
"NCT00006305",
"NCT00032487",
"NCT00283842"
] | 428 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Intervention Type: DRUG; Name: Inhibitors, ACE; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: amlodipine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: lisinopril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: doxazosin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chlorthalidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pravastatin; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A",
"B": "Arm Label: angiotensin receptor blockers; Type: ACTIVE_COMPARATOR; Interventions: Drug: Angiotensin receptor blockers | Arm Label: β-blockers; Type: ACTIVE_COMPARATOR; Interventions: Drug: β-blockers | Arm Label: thiazide diuretics; Type: ACTIVE_COMPARATOR; Interventions: Drug: thiazide diuretics | Intervention Type: DRUG; Name: Angiotensin receptor blockers; Assigned to Arm(s): angiotensin receptor blockers | Intervention Type: DRUG; Name: β-blockers; Assigned to Arm(s): β-blockers | Intervention Type: DRUG; Name: thiazide diuretics; Assigned to Arm(s): thiazide diuretics",
"C": "Arm Label: Atenolol; Type: EXPERIMENTAL; Interventions: Drug: Atenolol | Arm Label: Hydrochlorothiazide (HCTZ); Type: EXPERIMENTAL; Interventions: Drug: Hydrochlorothiazide | Intervention Type: DRUG; Name: Hydrochlorothiazide; Assigned to Arm(s): Hydrochlorothiazide (HCTZ) | Intervention Type: DRUG; Name: Atenolol; Assigned to Arm(s): Atenolol",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
D
|
[
"NCT00000542",
"NCT00135551",
"NCT00246519",
"NCT00032487"
] | 429 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"B": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"C": "Arm Label: BIAsp 30; Type: EXPERIMENTAL; Interventions: Drug: BIAsp 30 | Arm Label: NPH/Reg; Type: ACTIVE_COMPARATOR; Interventions: Drug: NPH/Reg | Intervention Type: DRUG; Name: BIAsp 30; Assigned to Arm(s): BIAsp 30 | Intervention Type: DRUG; Name: NPH/Reg; Assigned to Arm(s): NPH/Reg",
"D": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo"
}
|
B
|
[
"NCT00145925",
"NCT00032487",
"NCT01889095",
"NCT00000620"
] | 430 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"B": "Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): N/A",
"C": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"D": "Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00032487",
"NCT00318422",
"NCT00145925",
"NCT00360815"
] | 431 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"B": "Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg",
"C": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"D": "Arm Label: Tight glucose control; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Arm Label: Standard glucose control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Asp(B28)- | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Tight glucose control | Intervention Type: DRUG; Name: Insulin, Asp(B28)-; Assigned to Arm(s): Standard glucose control"
}
|
A
|
[
"NCT00032487",
"NCT01720446",
"NCT00145925",
"NCT01643382"
] | 432 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): 2",
"B": "Arm Label: Intensive Insulin therapy; Type: EXPERIMENTAL; Interventions: Other: Intensive Insulin Therapy | Arm Label: Conventional Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Insulin therapy | Intervention Type: OTHER; Name: Intensive Insulin Therapy; Assigned to Arm(s): Intensive Insulin therapy | Intervention Type: OTHER; Name: Conventional Insulin therapy; Assigned to Arm(s): Conventional Therapy",
"C": "Intervention Type: DRUG; Name: Insulin infusion with a goal; Assigned to Arm(s): N/A",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
D
|
[
"NCT00472381",
"NCT00220987",
"NCT00282698",
"NCT00032487"
] | 433 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: rosiglitazone; Assigned to Arm(s): N/A",
"C": "Arm Label: Linagliptin; Type: EXPERIMENTAL; Interventions: Drug: Linagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
D
|
[
"NCT00099931",
"NCT00054782",
"NCT00954447",
"NCT00032487"
] | 434 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): 1",
"B": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"C": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
D
|
[
"NCT00598013",
"NCT00000620",
"NCT00145925",
"NCT00032487"
] | 435 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"B": "Arm Label: Anti-VEGF+Deferred PRP; Type: EXPERIMENTAL; Interventions: Drug: 0.5-mg Ranibizumab, Other: Deferred panretinal photocoagulation | Arm Label: Prompt PRP; Type: ACTIVE_COMPARATOR; Interventions: Other: Prompt Panretinal Photocoagulation | Intervention Type: OTHER; Name: Prompt Panretinal Photocoagulation; Assigned to Arm(s): Prompt PRP | Intervention Type: DRUG; Name: 0.5-mg Ranibizumab; Assigned to Arm(s): Anti-VEGF+Deferred PRP | Intervention Type: OTHER; Name: Deferred panretinal photocoagulation; Assigned to Arm(s): Anti-VEGF+Deferred PRP",
"C": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"D": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo"
}
|
A
|
[
"NCT00032487",
"NCT01489189",
"NCT00145925",
"NCT00542178"
] | 436 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: Liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"C": "Arm Label: Revascularization and Insulin Providing (IP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Procedure: Coronary Artery Bypass, Drug: Insulin, sulfonylurea, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Revascularization and Insulin Sensitizing (IS); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions, Procedure: Coronary Artery Bypass, Drug: Biguanides, thiazolidinediones, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Medical Therapy and Insulin Providing (IP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, sulfonylurea, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Arm Label: Medical Therapy and Insulin Sensitizing (IS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Biguanides, thiazolidinediones, Drug: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers | Intervention Type: PROCEDURE; Name: Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions; Assigned to Arm(s): Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS) | Intervention Type: PROCEDURE; Name: Coronary Artery Bypass; Assigned to Arm(s): Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS) | Intervention Type: DRUG; Name: Biguanides, thiazolidinediones; Assigned to Arm(s): Medical Therapy and Insulin Sensitizing (IS), Revascularization and Insulin Sensitizing (IS) | Intervention Type: DRUG; Name: Insulin, sulfonylurea; Assigned to Arm(s): Medical Therapy and Insulin Providing (IP), Revascularization and Insulin Providing (IP) | Intervention Type: DRUG; Name: ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers; Assigned to Arm(s): Medical Therapy and Insulin Providing (IP), Medical Therapy and Insulin Sensitizing (IS), Revascularization and Insulin Providing (IP), Revascularization and Insulin Sensitizing (IS)",
"D": "Arm Label: T2D, Dialysis, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Dialysis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): T2D, Dialysis, Liraglutide, T2D, Dialysis, Placebo, T2D, Normal kidney function, Liraglutide, T2D, Normal kidney function, Placebo"
}
|
B
|
[
"NCT02545738",
"NCT00032487",
"NCT00006305",
"NCT01394341"
] | 437 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): N/A",
"B": "Arm Label: Insulin glargine + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: omega-3 polyunsaturated fatty acids (PUFA), Device: reusable pen device for insulin injection | Arm Label: Insulin glargine + placebo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (HOE901), Drug: placebo, Device: reusable pen device for insulin injection | Arm Label: Standard care + omega-3 polyunsaturated fatty acids; Type: EXPERIMENTAL; Interventions: Drug: omega-3 polyunsaturated fatty acids (PUFA) | Arm Label: Standard care + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: insulin glargine (HOE901); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo | Intervention Type: DRUG; Name: omega-3 polyunsaturated fatty acids (PUFA); Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Standard care + omega-3 polyunsaturated fatty acids | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Insulin glargine + placebo, Standard care + placebo | Intervention Type: DEVICE; Name: reusable pen device for insulin injection; Assigned to Arm(s): Insulin glargine + omega-3 polyunsaturated fatty acids, Insulin glargine + placebo",
"C": "Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group Self-Management Intervention (SMI); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management Intervention | Arm Label: SMI + Risk Results; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management Intervention, Behavioral: Risk Result | Intervention Type: BEHAVIORAL; Name: Self-Management Intervention; Assigned to Arm(s): Group Self-Management Intervention (SMI), SMI + Risk Results | Intervention Type: BEHAVIORAL; Name: Risk Result; Assigned to Arm(s): SMI + Risk Results",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
D
|
[
"NCT00220441",
"NCT00069784",
"NCT01891786",
"NCT00032487"
] | 438 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"B": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"C": "Intervention Type: BEHAVIORAL; Name: Insulin; Assigned to Arm(s): N/A",
"D": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control"
}
|
B
|
[
"NCT00000620",
"NCT00032487",
"NCT00360815",
"NCT00145925"
] | 439 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control",
"B": "N/A",
"C": "Arm Label: Intensive glycemia control; Type: EXPERIMENTAL; Interventions: Drug: Hypoglycemic Agents | Arm Label: Standard glycemia control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard glycemia control | Arm Label: Intensive BP control; Type: EXPERIMENTAL; Interventions: Drug: Intensive BP treatment | Arm Label: Standard BP control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard BP control | Arm Label: Fibrate; Type: EXPERIMENTAL; Interventions: Drug: Fenofibrate, Drug: Simvastatin | Arm Label: Fibrate Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Simvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Hypoglycemic Agents; Assigned to Arm(s): Intensive glycemia control | Intervention Type: DRUG; Name: Standard glycemia control; Assigned to Arm(s): Standard glycemia control | Intervention Type: DRUG; Name: Intensive BP treatment; Assigned to Arm(s): Intensive BP control | Intervention Type: DRUG; Name: Standard BP control; Assigned to Arm(s): Standard BP control | Intervention Type: DRUG; Name: Fenofibrate; Assigned to Arm(s): Fibrate | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Fibrate, Fibrate Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Fibrate Placebo",
"D": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control"
}
|
D
|
[
"NCT00145925",
"NCT00360893",
"NCT00542178",
"NCT00032487"
] | 440 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: 1 - Insulin glargine QHS; Type: EXPERIMENTAL; Interventions: Drug: 1- Insulin glargine QHS | Arm Label: 2 - Insulin glargine QAM; Type: EXPERIMENTAL; Interventions: Drug: 2 - Insulin glargine QAM | Arm Label: 3 - NPH Insulin QHS; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 - NPH insulin QHS | Intervention Type: DRUG; Name: 1- Insulin glargine QHS; Assigned to Arm(s): 1 - Insulin glargine QHS | Intervention Type: DRUG; Name: 2 - Insulin glargine QAM; Assigned to Arm(s): 2 - Insulin glargine QAM | Intervention Type: DRUG; Name: 3 - NPH insulin QHS; Assigned to Arm(s): 3 - NPH Insulin QHS",
"B": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"C": "Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Blood pressure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Perindopril-indapamide | Arm Label: Glucose control; Type: OTHER; Interventions: Drug: Gliclazide MR-based glucose lowering | Intervention Type: DRUG; Name: Perindopril-indapamide; Assigned to Arm(s): Blood pressure | Intervention Type: DRUG; Name: Gliclazide MR-based glucose lowering; Assigned to Arm(s): Glucose control"
}
|
B
|
[
"NCT00686712",
"NCT00032487",
"NCT01179048",
"NCT00145925"
] | 441 |
train
|
NCT00032487
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #465 - Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT)
Brief Summary: This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications.
|
{
"A": "Arm Label: Glycemia Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: Glycemia Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hyperglycemic Agents | Arm Label: BP Trial: intensive control; Type: EXPERIMENTAL; Interventions: Drug: Anti-hypertensive Agents | Arm Label: BP Trial: standard control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anti-hypertensive Agents | Arm Label: Lipid Trial: fenofibrate; Type: EXPERIMENTAL; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Arm Label: Lipid Trial: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Blinded fenofibrate or placebo plus simvastatin | Intervention Type: DRUG; Name: Anti-hyperglycemic Agents; Assigned to Arm(s): Glycemia Trial: intensive control, Glycemia Trial: standard control | Intervention Type: DRUG; Name: Anti-hypertensive Agents; Assigned to Arm(s): BP Trial: intensive control, BP Trial: standard control | Intervention Type: DRUG; Name: Blinded fenofibrate or placebo plus simvastatin; Assigned to Arm(s): Lipid Trial: fenofibrate, Lipid Trial: placebo",
"B": "Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control",
"C": "Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Colesevelam hydrochloride; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00000620",
"NCT00032487",
"NCT00147719",
"NCT00151749"
] | 442 |
train
|
NCT00032591
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #481 - The Home INR Study (THINRS)
Brief Summary: Since home monitors of prothrombin time (PT) may potentially improve the safety, quality, and convenience of chronic anticoagulation management, it is likely that there will be demands from providers, patients, and manufacturers to make home monitors available to VA patients. The rationale for patient self-testing (PST) is that, compared to conventional high quality anticoagulation management (HQACM), it would permit more intense monitoring and increased patient participation in his/her own care, resulting in increased precision in anticoagulation control and thus fewer events of thromboembolism (strokes) and bleeding. The secondary hypothesis is that PST and HQACM will be comparable in terms of health care utilization and cost.
|
{
"A": "Arm Label: Subject on Motivational Interview; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational interview | Arm Label: Subject Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Motivational interview; Assigned to Arm(s): Subject on Motivational Interview | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Subject Control",
"B": "Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: risk reduction | Arm Label: Delayed Intervention; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: risk reduction | Intervention Type: BEHAVIORAL; Name: risk reduction; Assigned to Arm(s): Delayed Intervention, Immediate Intervention",
"C": "Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-coordinated integrated care model for AF | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Nurse-coordinated integrated care model for AF; Assigned to Arm(s): Intervention group",
"D": "Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2"
}
|
D
|
[
"NCT02941978",
"NCT00128687",
"NCT03924739",
"NCT00032591"
] | 443 |
train
|
NCT00032591
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #481 - The Home INR Study (THINRS)
Brief Summary: Since home monitors of prothrombin time (PT) may potentially improve the safety, quality, and convenience of chronic anticoagulation management, it is likely that there will be demands from providers, patients, and manufacturers to make home monitors available to VA patients. The rationale for patient self-testing (PST) is that, compared to conventional high quality anticoagulation management (HQACM), it would permit more intense monitoring and increased patient participation in his/her own care, resulting in increased precision in anticoagulation control and thus fewer events of thromboembolism (strokes) and bleeding. The secondary hypothesis is that PST and HQACM will be comparable in terms of health care utilization and cost.
|
{
"A": "Arm Label: Warfarin/placebo edoxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin tablets, Drug: placebo edoxaban | Arm Label: high dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (high dose regimen-60mg), Drug: placebo warfarin | Arm Label: low dose edoxaban/placebo warfarin; Type: EXPERIMENTAL; Interventions: Drug: Edoxaban tablets (low dose regimen-30mg), Drug: placebo warfarin | Intervention Type: DRUG; Name: warfarin tablets; Assigned to Arm(s): Warfarin/placebo edoxaban | Intervention Type: DRUG; Name: Edoxaban tablets (high dose regimen-60mg); Assigned to Arm(s): high dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: Edoxaban tablets (low dose regimen-30mg); Assigned to Arm(s): low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo warfarin; Assigned to Arm(s): high dose edoxaban/placebo warfarin, low dose edoxaban/placebo warfarin | Intervention Type: DRUG; Name: placebo edoxaban; Assigned to Arm(s): Warfarin/placebo edoxaban",
"B": "Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2",
"C": "Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: Medication Education Tool | Intervention Type: OTHER; Name: Medication Education Tool; Assigned to Arm(s): 2",
"D": "Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management"
}
|
B
|
[
"NCT00781391",
"NCT00032591",
"NCT00408733",
"NCT01033279"
] | 444 |
train
|
NCT00032591
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #481 - The Home INR Study (THINRS)
Brief Summary: Since home monitors of prothrombin time (PT) may potentially improve the safety, quality, and convenience of chronic anticoagulation management, it is likely that there will be demands from providers, patients, and manufacturers to make home monitors available to VA patients. The rationale for patient self-testing (PST) is that, compared to conventional high quality anticoagulation management (HQACM), it would permit more intense monitoring and increased patient participation in his/her own care, resulting in increased precision in anticoagulation control and thus fewer events of thromboembolism (strokes) and bleeding. The secondary hypothesis is that PST and HQACM will be comparable in terms of health care utilization and cost.
|
{
"A": "Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Warfarin | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Group B",
"B": "Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 5mg, Drug: warfarin 1mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin",
"C": "Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Patient Self Testing; Type: ACTIVE_COMPARATOR; Interventions: Device: INRatio monitor by Hemosense | Intervention Type: DEVICE; Name: INRatio monitor by Hemosense; Assigned to Arm(s): Patient Self Testing | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care",
"D": "Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2"
}
|
D
|
[
"NCT00925028",
"NCT01505881",
"NCT00703963",
"NCT00032591"
] | 445 |
train
|
NCT00032617
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #494 - A Randomized Clinical Trial of Cognitive-Behavioral Treatment for PTSD in Women (PTSD)
Brief Summary: The purpose of the proposed DVA cooperative study is to evaluate the efficacy of exposure therapy for treating PTSD and associated problems in female veterans and active duty military personnel. We propose to compare exposure therapy, Prolonged Exposure, with a comparison therapy that focuses on current problems, Present Centered Therapy.
The study is a randomized clinical trial involving 384 female veterans and active duty personnel in 11 VA medical centers and 1 DoD medical center. All subjects, even self-referrals, will enter the study through referrals by mental health clinicians at the participating sites. Following informed consent, subjects will be screened for inclusion and exclusion diagnoses. If they meet these criteria and agree to participate, they will be randomly assigned to one of the two treatments, which will occur weekly for 10 weeks. Subjects will be assessed before treatment, immediately following treatment, and 3 and 6 months after the end of treatment. The primary outcome is PTSD severity. Secondary outcomes are anxiety and depression. Exploratory outcomes include associated features of PTSD, such as dissociation and substance abuse; psychosocial functioning, quality of life, physical health, satisfaction with treatment, and service utilization. Both treatments will be described in detail in a treatment manual and monitored intensively to ensure that they are administered correctly.
|
{
"A": "Arm Label: Arm 1: GCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Group Cognitive Behavioral Treatment (GCBT) | Arm Label: Arm 2: Group Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present Centered Group Treatment | Intervention Type: BEHAVIORAL; Name: Group Cognitive Behavioral Treatment (GCBT); Assigned to Arm(s): Arm 1: GCBT | Intervention Type: BEHAVIORAL; Name: Present Centered Group Treatment; Assigned to Arm(s): Arm 2: Group Treatment",
"B": "Arm Label: Mantram Repetition Program (MRP); Type: EXPERIMENTAL; Interventions: Behavioral: Mantram Repetition Program (MRP) | Arm Label: Present Centered Therapy (PCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present Centered Therapy (PCT) | Intervention Type: BEHAVIORAL; Name: Mantram Repetition Program (MRP); Assigned to Arm(s): Mantram Repetition Program (MRP) | Intervention Type: BEHAVIORAL; Name: Present Centered Therapy (PCT); Assigned to Arm(s): Present Centered Therapy (PCT)",
"C": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Therapy | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Present-Centered Therapy; Assigned to Arm(s): Arm 2",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prolonged Exposure | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Present Centered Therapy | Intervention Type: PROCEDURE; Name: Prolonged Exposure; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Present Centered Therapy; Assigned to Arm(s): 2"
}
|
D
|
[
"NCT01544088",
"NCT01506323",
"NCT00371644",
"NCT00032617"
] | 446 |
train
|
NCT00032617
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #494 - A Randomized Clinical Trial of Cognitive-Behavioral Treatment for PTSD in Women (PTSD)
Brief Summary: The purpose of the proposed DVA cooperative study is to evaluate the efficacy of exposure therapy for treating PTSD and associated problems in female veterans and active duty military personnel. We propose to compare exposure therapy, Prolonged Exposure, with a comparison therapy that focuses on current problems, Present Centered Therapy.
The study is a randomized clinical trial involving 384 female veterans and active duty personnel in 11 VA medical centers and 1 DoD medical center. All subjects, even self-referrals, will enter the study through referrals by mental health clinicians at the participating sites. Following informed consent, subjects will be screened for inclusion and exclusion diagnoses. If they meet these criteria and agree to participate, they will be randomly assigned to one of the two treatments, which will occur weekly for 10 weeks. Subjects will be assessed before treatment, immediately following treatment, and 3 and 6 months after the end of treatment. The primary outcome is PTSD severity. Secondary outcomes are anxiety and depression. Exploratory outcomes include associated features of PTSD, such as dissociation and substance abuse; psychosocial functioning, quality of life, physical health, satisfaction with treatment, and service utilization. Both treatments will be described in detail in a treatment manual and monitored intensively to ensure that they are administered correctly.
|
{
"A": "Arm Label: Control - VSLA; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control - Mental Health; Type: OTHER; Interventions: Behavioral: Treatment as usual | Arm Label: Voluntary Savings/Loans Assoc; Type: EXPERIMENTAL; Interventions: Behavioral: Voluntary Savings/Loans Assoc | Arm Label: Cognitive Processing Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Control - Mental Health | Intervention Type: BEHAVIORAL; Name: Voluntary Savings/Loans Assoc; Assigned to Arm(s): Voluntary Savings/Loans Assoc | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prolonged Exposure | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Present Centered Therapy | Intervention Type: PROCEDURE; Name: Prolonged Exposure; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Present Centered Therapy; Assigned to Arm(s): 2",
"C": "Intervention Type: BEHAVIORAL; Name: Cognitive Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Written Exposure; Assigned to Arm(s): N/A",
"D": "Arm Label: Mental health treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Improving AIDS Care after Trauma (ImpACT) | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Improving AIDS Care after Trauma (ImpACT); Assigned to Arm(s): Mental health treatment"
}
|
B
|
[
"NCT01385163",
"NCT00032617",
"NCT00245232",
"NCT02223390"
] | 447 |
train
|
NCT00032617
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CSP #494 - A Randomized Clinical Trial of Cognitive-Behavioral Treatment for PTSD in Women (PTSD)
Brief Summary: The purpose of the proposed DVA cooperative study is to evaluate the efficacy of exposure therapy for treating PTSD and associated problems in female veterans and active duty military personnel. We propose to compare exposure therapy, Prolonged Exposure, with a comparison therapy that focuses on current problems, Present Centered Therapy.
The study is a randomized clinical trial involving 384 female veterans and active duty personnel in 11 VA medical centers and 1 DoD medical center. All subjects, even self-referrals, will enter the study through referrals by mental health clinicians at the participating sites. Following informed consent, subjects will be screened for inclusion and exclusion diagnoses. If they meet these criteria and agree to participate, they will be randomly assigned to one of the two treatments, which will occur weekly for 10 weeks. Subjects will be assessed before treatment, immediately following treatment, and 3 and 6 months after the end of treatment. The primary outcome is PTSD severity. Secondary outcomes are anxiety and depression. Exploratory outcomes include associated features of PTSD, such as dissociation and substance abuse; psychosocial functioning, quality of life, physical health, satisfaction with treatment, and service utilization. Both treatments will be described in detail in a treatment manual and monitored intensively to ensure that they are administered correctly.
|
{
"A": "Arm Label: study arm; Type: EXPERIMENTAL; Interventions: Behavioral: Psychotherapy treatment | Intervention Type: BEHAVIORAL; Name: Psychotherapy treatment; Assigned to Arm(s): study arm",
"B": "Arm Label: MDMA-assisted therapy (125 mg); Type: EXPERIMENTAL; Interventions: Drug: Midomafetamine HCl, Behavioral: Therapy | Arm Label: Placebo with therapy; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose placebo pill, Behavioral: Therapy | Intervention Type: DRUG; Name: Midomafetamine HCl; Assigned to Arm(s): MDMA-assisted therapy (125 mg) | Intervention Type: DRUG; Name: Lactose placebo pill; Assigned to Arm(s): Placebo with therapy | Intervention Type: BEHAVIORAL; Name: Therapy; Assigned to Arm(s): MDMA-assisted therapy (125 mg), Placebo with therapy",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prolonged Exposure | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Present Centered Therapy | Intervention Type: PROCEDURE; Name: Prolonged Exposure; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Present Centered Therapy; Assigned to Arm(s): 2",
"D": "Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: NET | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: NET; Assigned to Arm(s): A"
}
|
C
|
[
"NCT00069381",
"NCT00090064",
"NCT00032617",
"NCT00563888"
] | 448 |
train
|
NCT00032786
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
|
{
"A": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A",
"C": "Arm Label: Vedolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Vedolizumab 6 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab 2 mg/kg, Vedolizumab 6 mg/kg",
"D": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A"
}
|
B
|
[
"NCT00783718",
"NCT00032786",
"NCT00619489",
"NCT00032799"
] | 449 |
train
|
NCT00032786
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
|
{
"A": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A",
"D": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT00783692",
"NCT00032799",
"NCT00032786",
"NCT00783718"
] | 450 |
train
|
NCT00032799
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
|
{
"A": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A",
"B": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A",
"D": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT00032786",
"NCT00783718",
"NCT00032799",
"NCT00783692"
] | 451 |
train
|
NCT00032799
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 International, Multicenter, Double-blind, Placebo-controlled Study of the Safety, Efficacy, and Tolerability of Intravenous Antegren (Natalizumab) in Subjects With Moderate to Severely Active Crohn's Disease
Brief Summary: The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
|
{
"A": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Rosiglitazone; Type: EXPERIMENTAL; Interventions: Drug: Rosiglitazone | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Rosiglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo",
"C": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00783692",
"NCT00065065",
"NCT00032786",
"NCT00032799"
] | 452 |
train
|
NCT00032890
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
Brief Summary: This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or chondroitin sulfate alone in the treatment of knee pain associated with osteoarthritis (OA) of the knee after six months of follow-up. These substances, marketed in the United States as dietary supplements, have been widely touted by the lay press and by anecdotal personal experience as effective in treating OA. To date, however, only a few small studies have been published in the worldwide literature. The study proposed herein has been carefully constructed to definitively determine the efficacy of these agents.
|
{
"A": "Intervention Type: DRUG; Name: glucosamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chondroitin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glucosamine and chondroitin sulfate combined; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): N/A",
"B": "Arm Label: buprenorphine transdermal system; Type: EXPERIMENTAL; Interventions: Drug: Buprenorphine | Arm Label: codeine paracetamol tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Codeine paracetamol | Intervention Type: DRUG; Name: Buprenorphine; Assigned to Arm(s): buprenorphine transdermal system | Intervention Type: DRUG; Name: Codeine paracetamol; Assigned to Arm(s): codeine paracetamol tablets",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: celecoxib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C",
"D": "Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol IR (CG5503) | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone IR | Arm Label: 004; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: 005; Type: EXPERIMENTAL; Interventions: Drug: Tapentadol ER (CG5503) | Arm Label: 006; Type: ACTIVE_COMPARATOR; Interventions: Drug: oxycodone CR | Arm Label: 007; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: oxycodone CR; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: oxycodone IR; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Tapentadol ER (CG5503); Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Tapentadol IR (CG5503); Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 007"
}
|
A
|
[
"NCT00032890",
"NCT00324038",
"NCT00484718",
"NCT00784277"
] | 453 |
train
|
NCT00032890
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT)
Brief Summary: This study will determine whether glucosamine, chondroitin sulfate and/or the combination of glucosamine and chondroitin sulfate are more effective than placebo and whether the combination is more effective than glucosamine or chondroitin sulfate alone in the treatment of knee pain associated with osteoarthritis (OA) of the knee after six months of follow-up. These substances, marketed in the United States as dietary supplements, have been widely touted by the lay press and by anecdotal personal experience as effective in treating OA. To date, however, only a few small studies have been published in the worldwide literature. The study proposed herein has been carefully constructed to definitively determine the efficacy of these agents.
|
{
"A": "Intervention Type: DRUG; Name: glucosamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: chondroitin sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glucosamine and chondroitin sulfate combined; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: celecoxib; Assigned to Arm(s): N/A",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Diet, Other: Exercise | Arm Label: Active Supplement; Type: ACTIVE_COMPARATOR; Interventions: Other: Diet, Other: Exercise | Intervention Type: OTHER; Name: Diet; Assigned to Arm(s): Active Supplement, Placebo | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Active Supplement, Placebo",
"C": "Intervention Type: DRUG; Name: Glucosamine sulfate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A",
"D": "Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Chondroitin sulphate | Intervention Type: DRUG; Name: Chondroitin sulphate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2"
}
|
A
|
[
"NCT00032890",
"NCT01271218",
"NCT00110474",
"NCT00669123"
] | 454 |
train
|
NCT00033592
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention
Brief Summary: RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking.
PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
|
{
"A": "Arm Label: Arm I: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm II: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm III: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IV: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm V: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VI: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm VII: placebo inhaler; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VIII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IX: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm X: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm XI: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XIII: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XIV: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XV: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IX: placebo inhaler cartridges, Arm V: placebo, Arm VII: placebo inhaler, Arm XI: placebo, Arm XIII: placebo inhaler cartridges, Arm XV: placebo inhaler cartridges | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): Arm II: bupropion, Arm IV: bupropion, Arm X: bupropion | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm I: nicotine inhaler cartridges, Arm III: nicotine inhaler cartridges, Arm VI: nicotine inhaler cartridges, Arm VIII: nicotine inhaler cartridges, Arm XII: nicotine inhaler cartridges, Arm XIV: nicotine inhaler cartridges",
"B": "Arm Label: Extended treatment; Type: EXPERIMENTAL; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Arm Label: Standard treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline, Behavioral: Individual smoking cessation counseling | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Extended treatment, Standard treatment | Intervention Type: BEHAVIORAL; Name: Individual smoking cessation counseling; Assigned to Arm(s): Extended treatment, Standard treatment",
"C": "Arm Label: Active bupropion-Active gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + nicotine gum | Arm Label: Active bupropion-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion-Placebo gum | Arm Label: Placebo medication-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo bupropion-Placebo gum | Intervention Type: DRUG; Name: bupropion + nicotine gum; Assigned to Arm(s): Active bupropion-Active gum | Intervention Type: DRUG; Name: Active bupropion-Placebo gum; Assigned to Arm(s): Active bupropion-Placebo gum | Intervention Type: DRUG; Name: Placebo bupropion-Placebo gum; Assigned to Arm(s): Placebo medication-Placebo gum",
"D": "Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo"
}
|
A
|
[
"NCT00033592",
"NCT00828113",
"NCT01621022",
"NCT00554840"
] | 455 |
train
|
NCT00033592
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention
Brief Summary: RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking.
PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
|
{
"A": "Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management",
"B": "Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR",
"C": "Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A",
"D": "Arm Label: Arm I: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm II: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm III: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IV: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm V: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VI: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm VII: placebo inhaler; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VIII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IX: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm X: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm XI: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XIII: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XIV: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XV: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IX: placebo inhaler cartridges, Arm V: placebo, Arm VII: placebo inhaler, Arm XI: placebo, Arm XIII: placebo inhaler cartridges, Arm XV: placebo inhaler cartridges | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): Arm II: bupropion, Arm IV: bupropion, Arm X: bupropion | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm I: nicotine inhaler cartridges, Arm III: nicotine inhaler cartridges, Arm VI: nicotine inhaler cartridges, Arm VIII: nicotine inhaler cartridges, Arm XII: nicotine inhaler cartridges, Arm XIV: nicotine inhaler cartridges"
}
|
D
|
[
"NCT00330187",
"NCT00935818",
"NCT00356967",
"NCT00033592"
] | 456 |
train
|
NCT00033592
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention
Brief Summary: RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking.
PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
|
{
"A": "Arm Label: Arm I: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm II: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm III: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IV: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm V: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VI: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm VII: placebo inhaler; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VIII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IX: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm X: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm XI: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XIII: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XIV: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XV: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IX: placebo inhaler cartridges, Arm V: placebo, Arm VII: placebo inhaler, Arm XI: placebo, Arm XIII: placebo inhaler cartridges, Arm XV: placebo inhaler cartridges | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): Arm II: bupropion, Arm IV: bupropion, Arm X: bupropion | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm I: nicotine inhaler cartridges, Arm III: nicotine inhaler cartridges, Arm VI: nicotine inhaler cartridges, Arm VIII: nicotine inhaler cartridges, Arm XII: nicotine inhaler cartridges, Arm XIV: nicotine inhaler cartridges",
"B": "Arm Label: Bupropion SR + Contingency Management; Type: EXPERIMENTAL; Interventions: Drug: Bupropion SR, Behavioral: Contingency Management | Arm Label: Placebo + Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Contingency Management, Other: Placebo | Arm Label: Bupropion SR + No Contingency Management; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion SR | Arm Label: Placebo + No Contingency Management; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Bupropion SR; Assigned to Arm(s): Bupropion SR + Contingency Management, Bupropion SR + No Contingency Management | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): Bupropion SR + Contingency Management, Placebo + Contingency Management | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo + Contingency Management, Placebo + No Contingency Management",
"C": "Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo",
"D": "Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00033592",
"NCT00330187",
"NCT01078298",
"NCT00044434"
] | 457 |
train
|
NCT00033592
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention
Brief Summary: RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking.
PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
|
{
"A": "Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment",
"B": "Arm Label: Arm I: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm II: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm III: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IV: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm V: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VI: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm VII: placebo inhaler; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VIII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IX: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm X: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm XI: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XIII: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XIV: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XV: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IX: placebo inhaler cartridges, Arm V: placebo, Arm VII: placebo inhaler, Arm XI: placebo, Arm XIII: placebo inhaler cartridges, Arm XV: placebo inhaler cartridges | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): Arm II: bupropion, Arm IV: bupropion, Arm X: bupropion | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm I: nicotine inhaler cartridges, Arm III: nicotine inhaler cartridges, Arm VI: nicotine inhaler cartridges, Arm VIII: nicotine inhaler cartridges, Arm XII: nicotine inhaler cartridges, Arm XIV: nicotine inhaler cartridges",
"C": "Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Nicotine Replacement Therapy Responder; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine Patches | Arm Label: Pre-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit) | Arm Label: Pre-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Pre-Quit) | Arm Label: Pre-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Pre-Quit) | Arm Label: Post-Quit Rescue to Bupropion & Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit) | Arm Label: Post-Quit Rescue to Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then varenicline (Post-Quit) | Arm Label: Post-Quit Rescue to Nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, then nicotine patches (Post-Quit) | Intervention Type: DRUG; Name: Nicotine Patches; Assigned to Arm(s): Nicotine Replacement Therapy Responder | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Pre-Quit); Assigned to Arm(s): Pre-Quit Rescue to Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then bupropion & nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Bupropion & Nicotine | Intervention Type: DRUG; Name: Nicotine patches, then varenicline (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Varenicline | Intervention Type: DRUG; Name: Nicotine patches, then nicotine patches (Post-Quit); Assigned to Arm(s): Post-Quit Rescue to Nicotine"
}
|
B
|
[
"NCT00364156",
"NCT00033592",
"NCT01370356",
"NCT00894166"
] | 458 |
train
|
NCT00033592
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Trial Comparing Nicotine Inhaler Versus Bupropion Versus Nicotine Inhaler Plus Bupropion For Smoking Cessation Efficacy And Relapse Prevention
Brief Summary: RATIONALE: Use of a nicotine inhaler and/or bupropion may be effective in helping people stop smoking and prevent them from starting smoking again. It is not yet known whether a nicotine inhaler or bupropion are more effective alone or combined for stopping smoking.
PURPOSE: Randomized phase III trial to compare the effectiveness of the nicotine inhaler or bupropion alone to that of the nicotine inhaler combined with bupropion in helping people to stop smoking and prevent starting smoking again.
|
{
"A": "Arm Label: Arm I: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm II: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm III: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IV: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm V: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VI: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm VII: placebo inhaler; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm VIII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm IX: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm X: bupropion; Type: EXPERIMENTAL; Interventions: Drug: bupropion hydrochloride | Arm Label: Arm XI: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XII: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XIII: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Arm XIV: nicotine inhaler cartridges; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: Arm XV: placebo inhaler cartridges; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IX: placebo inhaler cartridges, Arm V: placebo, Arm VII: placebo inhaler, Arm XI: placebo, Arm XIII: placebo inhaler cartridges, Arm XV: placebo inhaler cartridges | Intervention Type: DRUG; Name: bupropion hydrochloride; Assigned to Arm(s): Arm II: bupropion, Arm IV: bupropion, Arm X: bupropion | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Arm I: nicotine inhaler cartridges, Arm III: nicotine inhaler cartridges, Arm VI: nicotine inhaler cartridges, Arm VIII: nicotine inhaler cartridges, Arm XII: nicotine inhaler cartridges, Arm XIV: nicotine inhaler cartridges",
"B": "Arm Label: 1: Bup+MM; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Medication Management, Drug: placebo patch | Arm Label: 2 Bup+Mayo; Type: EXPERIMENTAL; Interventions: Drug: bupropion, Behavioral: Mayo Counseling, Drug: placebo patch | Arm Label: 3 Patch+MM; Type: PLACEBO_COMPARATOR; Interventions: Drug: nicotine transdermal system, Behavioral: Medication Management, Drug: placebo bupropion | Arm Label: 4 Patch+Mayo; Type: EXPERIMENTAL; Interventions: Drug: nicotine transdermal system, Behavioral: Mayo Counseling, Drug: placebo bupropion | Intervention Type: DRUG; Name: nicotine transdermal system; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: BEHAVIORAL; Name: Medication Management; Assigned to Arm(s): 1: Bup+MM, 3 Patch+MM | Intervention Type: BEHAVIORAL; Name: Mayo Counseling; Assigned to Arm(s): 2 Bup+Mayo, 4 Patch+Mayo | Intervention Type: DRUG; Name: placebo patch; Assigned to Arm(s): 1: Bup+MM, 2 Bup+Mayo | Intervention Type: DRUG; Name: placebo bupropion; Assigned to Arm(s): 3 Patch+MM, 4 Patch+Mayo",
"C": "Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)",
"D": "Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00033592",
"NCT00086411",
"NCT01771627",
"NCT00813917"
] | 459 |
train
|
NCT00033605
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy
Brief Summary: RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing radiation therapy to the pelvis. It is not yet known whether octreotide is effective for diarrhea.
PURPOSE: Randomized phase III trial to determine the effectiveness of octreotide in preventing diarrhea in patients who are undergoing radiation therapy to the pelvis.
|
{
"A": "Arm Label: octreotide + radiation; Type: EXPERIMENTAL; Interventions: Drug: octreotide acetate, Radiation: radiation | Arm Label: placebo + radiation; Type: ACTIVE_COMPARATOR; Interventions: Other: placebo, Radiation: radiation | Intervention Type: DRUG; Name: octreotide acetate; Assigned to Arm(s): octreotide + radiation | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo + radiation | Intervention Type: RADIATION; Name: radiation; Assigned to Arm(s): octreotide + radiation, placebo + radiation",
"B": "Arm Label: Arm I: Sulfasalazine; Type: EXPERIMENTAL; Interventions: Drug: sulfasalazine | Arm Label: Arm II: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): Arm I: Sulfasalazine | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II: Placebo",
"C": "Arm Label: Bifilact® probiotics standard dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bifilact® | Arm Label: Bifilact® probiotics high dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bifilact® | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: Bifilact®; Assigned to Arm(s): Bifilact® probiotics high dose, Bifilact® probiotics standard dose | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo",
"D": "Arm Label: Arm Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm Soy Supplement; Type: EXPERIMENTAL; Interventions: Drug: Soy Supplement | Intervention Type: DRUG; Name: Soy Supplement; Assigned to Arm(s): Arm Soy Supplement | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm Placebo"
}
|
A
|
[
"NCT00033605",
"NCT01198145",
"NCT01839721",
"NCT00255125"
] | 460 |
train
|
NCT00033631
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study Of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT In Patients Treated For Localized Prostate Cancer
Brief Summary: RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which dose of radiation therapy is more effective in treating stage II prostate cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of two different doses of specialized radiation therapy in treating patients who have stage II prostate cancer.
|
{
"A": "Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A",
"B": "Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I, Arm II",
"C": "Arm Label: Intensity Modulated Radiotherapy (IMRT); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy | Arm Label: Hypofractionated Intensity Modulated Radiotherapy (HIMRT); Type: EXPERIMENTAL; Interventions: Radiation: Hypofractionated Intensity Modulated Radiotherapy | Intervention Type: RADIATION; Name: Conventional Fractionated Intensity Modulated Radiotherapy; Assigned to Arm(s): Intensity Modulated Radiotherapy (IMRT) | Intervention Type: RADIATION; Name: Hypofractionated Intensity Modulated Radiotherapy; Assigned to Arm(s): Hypofractionated Intensity Modulated Radiotherapy (HIMRT)",
"D": "Arm Label: 70.2 Gy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: 70.2 Gy 3D-CRT/IMRT | Arm Label: 79.2 Gy; Type: EXPERIMENTAL; Interventions: Radiation: 79.2 Gy 3D-CRT/IMRT | Intervention Type: RADIATION; Name: 70.2 Gy 3D-CRT/IMRT; Assigned to Arm(s): 70.2 Gy | Intervention Type: RADIATION; Name: 79.2 Gy 3D-CRT/IMRT; Assigned to Arm(s): 79.2 Gy"
}
|
D
|
[
"NCT00010244",
"NCT00967863",
"NCT00667888",
"NCT00033631"
] | 461 |
train
|
NCT00033904
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma
Brief Summary: Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
|
{
"A": "Arm Label: Cohort A: MSI Positive Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort B: MSI Negative Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort C: MSI Positive Non-Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Intervention Type: DRUG; Name: MK-3475; Assigned to Arm(s): Cohort A: MSI Positive Colorectal Cancer, Cohort B: MSI Negative Colorectal Cancer, Cohort C: MSI Positive Non-Colorectal Cancer",
"B": "Intervention Type: DRUG; Name: autologous human tumor-derived HSPPC-96; Assigned to Arm(s): N/A",
"C": "Arm Label: 1: AGS-003+sunitinib; Type: EXPERIMENTAL; Interventions: Biological: AGS-003, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): 1: AGS-003+sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1: AGS-003+sunitinib",
"D": "Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1"
}
|
B
|
[
"NCT01876511",
"NCT00033904",
"NCT00678119",
"NCT00083889"
] | 462 |
train
|
NCT00034736
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting
Brief Summary: The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.
|
{
"A": "Intervention Type: DRUG; Name: Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.; Assigned to Arm(s): N/A",
"B": "Arm Label: amoxicillin/clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin/clavulanic acid | Arm Label: ceftriaxone/oxacillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ceftriaxone/oxacillin | Intervention Type: DRUG; Name: Amoxycillin/clavulanic acid; Assigned to Arm(s): amoxicillin/clavulanic acid | Intervention Type: DRUG; Name: ceftriaxone/oxacillin; Assigned to Arm(s): ceftriaxone/oxacillin",
"C": "Arm Label: Intervention; Type: OTHER; Interventions: Drug: Amoxicillin | Arm Label: Control; Type: OTHER; Interventions: Other: Referral to Health facility | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Referral to Health facility; Assigned to Arm(s): Control",
"D": "Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00396526",
"NCT01166932",
"NCT01192789",
"NCT00034736"
] | 463 |
train
|
NCT00034749
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
Brief Summary: A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.
|
{
"A": "Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone",
"B": "Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A",
"C": "Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE",
"D": "Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00053703",
"NCT00204087",
"NCT02090335",
"NCT00034749"
] | 464 |
train
|
NCT00034749
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
Brief Summary: A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.
|
{
"A": "Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group",
"B": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A",
"D": "Intervention Type: DRUG; Name: Quetiapine Fumarate; Assigned to Arm(s): N/A"
}
|
C
|
[
"NCT00102063",
"NCT00051298",
"NCT00034749",
"NCT00449397"
] | 465 |
train
|
NCT00035204
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)
Brief Summary: The purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.
|
{
"A": "Arm Label: Zolpidem CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem CR; Assigned to Arm(s): Zolpidem CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Intervention Type: DRUG; Name: galantamine; Assigned to Arm(s): N/A",
"C": "Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GammaSense Stimulation System (Active Settings) | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Device: GammaSense Stimulation System (Sham Settings) | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Active Settings); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Sham Settings); Assigned to Arm(s): Control Group"
}
|
B
|
[
"NCT00814502",
"NCT00035204",
"NCT01142258",
"NCT03556280"
] | 466 |
train
|
NCT00035308
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Brief Summary: The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.
|
{
"A": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 811 | Arm Label: AMG811; Type: OTHER; Interventions: Drug: AMG 811 | Intervention Type: DRUG; Name: AMG 811; Assigned to Arm(s): AMG811, Placebo",
"B": "Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil",
"C": "Arm Label: FK506+MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Multitherapy | Intervention Type: DRUG; Name: Multitherapy; Assigned to Arm(s): FK506+MMF",
"D": "Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A"
}
|
D
|
[
"NCT00818948",
"NCT00371319",
"NCT00298506",
"NCT00035308"
] | 467 |
train
|
NCT00035321
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features
Brief Summary: The purposes of this study are to determine:
* Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
* The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination.
* The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.
|
{
"A": "Arm Label: lithium plus usual care; Type: EXPERIMENTAL; Interventions: Drug: lithium | Arm Label: usual care without lithium therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: usual care | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): lithium plus usual care | Intervention Type: DRUG; Name: usual care; Assigned to Arm(s): usual care without lithium therapy",
"B": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A",
"C": "Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A",
"D": "Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2"
}
|
B
|
[
"NCT00927550",
"NCT00035321",
"NCT01360632",
"NCT00105196"
] | 468 |
train
|
NCT00035568
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (Phase A)/Metformin (Phase B) | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d. | Intervention Type: DRUG; Name: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily); Assigned to Arm(s): 4, 5 | Intervention Type: DRUG; Name: Comparator: MK0431 100 mg q.d. (q.d. = once daily); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo (Phase A)/Metformin (Phase B); Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Comparator: Metformin 500 mg b.i.d.; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: Comparator: Metformin 1000 mg b.i.d.; Assigned to Arm(s): 3, 5",
"B": "Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glipizide | Arm Label: glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): glipizide",
"C": "Intervention Type: DRUG; Name: Glucovance (metformin HCl/glyburide); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Metformin HCl alone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Glyburide alone.; Assigned to Arm(s): N/A",
"D": "Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin"
}
|
C
|
[
"NCT00103857",
"NCT00513630",
"NCT00035568",
"NCT01779375"
] | 469 |
train
|
NCT00035906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
|
{
"A": "Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2",
"C": "Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg",
"D": "Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care"
}
|
A
|
[
"NCT00035906",
"NCT00132691",
"NCT00407082",
"NCT00468871"
] | 470 |
train
|
NCT00035906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
|
{
"A": "Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A",
"D": "Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser"
}
|
A
|
[
"NCT00035906",
"NCT00370422",
"NCT00370669",
"NCT00687804"
] | 471 |
train
|
NCT00035906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
|
{
"A": "Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab",
"B": "Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A",
"C": "Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A",
"D": "Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Bevacizumab | Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Bevacizumab, Ranibizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab, Ranibizumab"
}
|
C
|
[
"NCT00407381",
"NCT02194803",
"NCT00035906",
"NCT01635790"
] | 472 |
train
|
NCT00035906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
|
{
"A": "Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A",
"B": "Arm Label: Sham injection plus laser; Type: EXPERIMENTAL; Interventions: Behavioral: Sham injection, Procedure: Focal/grid laser | Arm Label: 0.5mg Ranibizumab plus laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Focal/grid laser | Arm Label: 4-mg Triamcinolone Acetonide plus Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Triamcinolone Acetonide, Procedure: Focal/grid laser | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): 0.5mg Ranibizumab plus laser | Intervention Type: DRUG; Name: Triamcinolone Acetonide; Assigned to Arm(s): 4-mg Triamcinolone Acetonide plus Laser | Intervention Type: BEHAVIORAL; Name: Sham injection; Assigned to Arm(s): Sham injection plus laser | Intervention Type: PROCEDURE; Name: Focal/grid laser; Assigned to Arm(s): 0.5mg Ranibizumab plus laser, 4-mg Triamcinolone Acetonide plus Laser, Sham injection plus laser",
"C": "Arm Label: Dexamethasone 700 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Dexamethasone 350 μg; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Other: Sham | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone 350 μg, Dexamethasone 700 μg | Intervention Type: OTHER; Name: Sham; Assigned to Arm(s): Sham",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser Photocoagulation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab | Intervention Type: PROCEDURE; Name: Laser Photocoagulation; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 5"
}
|
A
|
[
"NCT00035906",
"NCT00445003",
"NCT00168337",
"NCT00336323"
] | 473 |
train
|
NCT00035906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
|
{
"A": "Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A",
"B": "Arm Label: sham injection; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Arm Label: FAI insert; Type: EXPERIMENTAL; Interventions: Drug: FAI insert | Intervention Type: DRUG; Name: FAI insert; Assigned to Arm(s): FAI insert | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): sham injection",
"C": "Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg",
"D": "Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care"
}
|
A
|
[
"NCT00035906",
"NCT01694186",
"NCT00407082",
"NCT00468871"
] | 474 |
train
|
NCT00035906
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.
Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.
There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.
|
{
"A": "Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A",
"B": "Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care",
"C": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2",
"D": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dexamethasone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: dexamethasone | Arm Label: 3; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): 3"
}
|
A
|
[
"NCT00035906",
"NCT00468871",
"NCT00132691",
"NCT00333814"
] | 475 |
train
|
NCT00036114
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
|
{
"A": "Arm Label: Audit + Feedback; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Audit + Feedback | Arm Label: Audit + Feedback + Educational Outreach; Type: EXPERIMENTAL; Interventions: Behavioral: Audit + Feedback, Behavioral: Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback; Assigned to Arm(s): Audit + Feedback, Audit + Feedback + Educational Outreach | Intervention Type: BEHAVIORAL; Name: Audit + Feedback + Educational Outreach; Assigned to Arm(s): Audit + Feedback + Educational Outreach",
"B": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A",
"D": "Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication, Behavioral: Systematic Pain Assessment and Treatment, Behavioral: Medication Review, Behavioral: Occupational therapy, Behavioral: Safety | Intervention Type: BEHAVIORAL; Name: Communication; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Systematic Pain Assessment and Treatment; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Medication Review; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Occupational therapy; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Safety; Assigned to Arm(s): Intervention"
}
|
C
|
[
"NCT02604056",
"NCT00015548",
"NCT00036114",
"NCT02238652"
] | 476 |
train
|
NCT00036114
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to learn if aripiprazole is safe and effective in the treatment of psychosis associated with dementia of the Alzheimer's type.
|
{
"A": "Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Arm Label: Brexpiprazole 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Arm Label: Brexpiprazole 2 mg; Type: EXPERIMENTAL; Interventions: Drug: Brexpiprazole, OPC-34712 | Intervention Type: DRUG; Name: Brexpiprazole, OPC-34712; Assigned to Arm(s): Brexpiprazole 1 mg, Brexpiprazole 2 mg | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo",
"C": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pimavanserin 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Pimavanserin tartrate | Intervention Type: DRUG; Name: Pimavanserin tartrate; Assigned to Arm(s): Pimavanserin 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"D": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00036114",
"NCT01862640",
"NCT02035553",
"NCT00015548"
] | 477 |
train
|
NCT00036127
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Study to learn if the alternate formulation is effective in agitated schizophrenic patients
|
{
"A": "Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A",
"B": "Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A",
"D": "Arm Label: ALKS 9072; Type: EXPERIMENTAL; Interventions: Drug: ALKS 9072 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ALKS 9072; Assigned to Arm(s): ALKS 9072 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
C
|
[
"NCT00103571",
"NCT00455234",
"NCT00036127",
"NCT01469039"
] | 478 |
train
|
NCT00036127
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Study to learn if the alternate formulation is effective in agitated schizophrenic patients
|
{
"A": "Arm Label: clozapine; Type: EXPERIMENTAL; Interventions: Drug: Clozapine | Arm Label: Olanzapine; Type: EXPERIMENTAL; Interventions: Drug: Olanzapine | Arm Label: Haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Haloperidol | Intervention Type: DRUG; Name: Clozapine; Assigned to Arm(s): clozapine | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): Olanzapine | Intervention Type: DRUG; Name: Haloperidol; Assigned to Arm(s): Haloperidol",
"B": "Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A",
"D": "Arm Label: Intramuscular ziprasidone; Type: EXPERIMENTAL; Interventions: Drug: Intramuscular ziprasidone mesylate | Arm Label: Intramuscular haloperidol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intramuscular haloperidol | Intervention Type: DRUG; Name: Intramuscular ziprasidone mesylate; Assigned to Arm(s): Intramuscular ziprasidone | Intervention Type: DRUG; Name: Intramuscular haloperidol; Assigned to Arm(s): Intramuscular haloperidol"
}
|
C
|
[
"NCT01123408",
"NCT00455234",
"NCT00036127",
"NCT00723606"
] | 479 |
train
|
NCT00036439
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
|
{
"A": "Arm Label: Cohort 1: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 2: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Cohort 3: Induction; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Maintenance; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Anti-IP-10 Antibody | Arm Label: Open Label; Type: OTHER; Interventions: Drug: Anti-IP-10 Antibody | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1: Induction, Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 1: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Cohort 2: Induction, Cohort 3: Induction | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Maintenance | Intervention Type: DRUG; Name: Anti-IP-10 Antibody; Assigned to Arm(s): Open Label",
"B": "Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: Budesonide MMX® 9 mg | Arm Label: 3: Entocort EC® 3 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Entocort EC® 3 mg | Arm Label: 4: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Entocort EC® 3 mg, 4: Placebo | Intervention Type: DRUG; Name: Budesonide MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: Budesonide MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Entocort EC® 3 mg; Assigned to Arm(s): 3: Entocort EC® 3 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4: Placebo",
"C": "Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A",
"D": "Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: sterile saline for injection | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: MDX-1100 | Intervention Type: BIOLOGICAL; Name: sterile saline for injection; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: MDX-1100; Assigned to Arm(s): 1"
}
|
C
|
[
"NCT01294410",
"NCT00679380",
"NCT00036439",
"NCT00656890"
] | 480 |
train
|
NCT00036439
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3",
"B": "Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A",
"C": "Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A",
"D": "Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo (control procedure) | Arm Label: Epidural injection of etanercept; Type: EXPERIMENTAL; Interventions: Drug: epidural injection of etanercept | Intervention Type: DRUG; Name: epidural injection of etanercept; Assigned to Arm(s): Epidural injection of etanercept | Intervention Type: DRUG; Name: placebo (control procedure); Assigned to Arm(s): 1"
}
|
B
|
[
"NCT00106548",
"NCT00036439",
"NCT00111449",
"NCT00364572"
] | 481 |
train
|
NCT00036439
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
|
{
"A": "Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A",
"B": "Arm Label: 1: budesonide-MMX® 6 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 6 mg | Arm Label: 2: budesonide-MMX® 9 mg; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, endoscopy, Drug: budesonide-MMX® 9 mg | Arm Label: 3: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Placebo | Arm Label: 4: Asacol® 400 mg; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Blood sampling, endoscopy, Drug: Asacol® 400 mg | Intervention Type: PROCEDURE; Name: Blood sampling, endoscopy; Assigned to Arm(s): 1: budesonide-MMX® 6 mg, 2: budesonide-MMX® 9 mg, 3: Placebo, 4: Asacol® 400 mg | Intervention Type: DRUG; Name: budesonide-MMX® 6 mg; Assigned to Arm(s): 1: budesonide-MMX® 6 mg | Intervention Type: DRUG; Name: budesonide-MMX® 9 mg; Assigned to Arm(s): 2: budesonide-MMX® 9 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3: Placebo | Intervention Type: DRUG; Name: Asacol® 400 mg; Assigned to Arm(s): 4: Asacol® 400 mg",
"C": "Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A",
"D": "Arm Label: Vedolizumab; Type: EXPERIMENTAL; Interventions: Drug: vedolizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: vedolizumab; Assigned to Arm(s): Vedolizumab | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00036439",
"NCT00679432",
"NCT00096655",
"NCT00783718"
] | 482 |
train
|
NCT00036439
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in Patients With Active Ulcerative Colitis
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of infliximab (Remicade) in patients with Ulcerative Colitis.
|
{
"A": "Arm Label: Adalimumab 80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Adalimumab 160/80/40; Type: EXPERIMENTAL; Interventions: Biological: adalimumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: placebo | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 80/40 | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab 160/80/40 | Intervention Type: BIOLOGICAL; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1 (i); Type: ACTIVE_COMPARATOR; Interventions: Drug: Rituximab | Arm Label: 2 (ii); Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): 1 (i), 2 (ii)",
"C": "Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Golimumab 100 mg -> 50 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 50 mg | Arm Label: Golimumab 200 mg -> 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 100 mg, Biological: Golimumab 200 mg | Arm Label: Golimumab 400 mg -> 200 mg; Type: EXPERIMENTAL; Interventions: Biological: Golimumab 200 mg, Biological: Golimumab 400 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg, Golimumab 200 mg -> 100 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 200 mg; Assigned to Arm(s): Golimumab 200 mg -> 100 mg, Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 400 mg; Assigned to Arm(s): Golimumab 400 mg -> 200 mg | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg; Assigned to Arm(s): Golimumab 100 mg -> 50 mg"
}
|
C
|
[
"NCT00385736",
"NCT00261118",
"NCT00036439",
"NCT00487539"
] | 483 |
train
|
NCT00037973
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Ventilation-Feedback Training on Exercise Performance in COPD
Brief Summary: The primary objective of the study is to determine whether individuals with Chronic Obstructive Pulmonary Disease (COPD) who complete ventilation-feedback training combined with a moderately-high intensity exercise and upper body strength program will demonstrate significantly longer exercise duration on a constant work rate treadmill test when compared to subjects who are randomly assigned to a moderately-high intensity exercise and upper body strength training program without ventilation-feedback or ventilation-feedback only. Secondary study objectives are to determine whether individuals with COPD who complete ventilation-feedback training combined with a moderately-high intensity exercise and upper body strength training program will demonstrate significantly: (a) greater exercise tolerance and aerobic power; (b) lower perception of breathlessness during progressive and constant work rate leg-cycle and treadmill exercise testing; (c) higher tidal volume and lower breathing frequency during constant work rate and at any given workload during progressive testing; (d) lower score on the Chronic Respiratory Disease Questionnaire indicating improved quality of life; (e) higher transition focal score (less dyspnea) on the Transition Dyspnea Index; (f) maintain a sustained breathing-pattern adjustment to exercise when compared to subjects who are randomly assigned to a moderately-high intensity exercise and upper body strength program without ventilation-feedback or ventilation-feedback only.
|
{
"A": "Arm Label: I; Type: EXPERIMENTAL; Interventions: Device: Conical Positive Expiratory Pressure Device (C-PEP) | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Other: Control breathing | Intervention Type: DEVICE; Name: Conical Positive Expiratory Pressure Device (C-PEP); Assigned to Arm(s): I | Intervention Type: OTHER; Name: Control breathing; Assigned to Arm(s): C",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ventilation feedback, Behavioral: exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: exercise | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ventilation feedback | Intervention Type: BEHAVIORAL; Name: ventilation feedback; Assigned to Arm(s): 1, 3 | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): 1, 2",
"C": "Arm Label: FT; Type: EXPERIMENTAL; Interventions: Behavioral: Breathlessness Intervention Service (BIS) | Arm Label: WL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Best supportive care (Standard care) | Intervention Type: BEHAVIORAL; Name: Breathlessness Intervention Service (BIS); Assigned to Arm(s): FT | Intervention Type: BEHAVIORAL; Name: Best supportive care (Standard care); Assigned to Arm(s): WL",
"D": "Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Diaphragmatic breathing training; Type: EXPERIMENTAL; Interventions: Other: Diaphragmatic breathing training | Intervention Type: OTHER; Name: Diaphragmatic breathing training; Assigned to Arm(s): Diaphragmatic breathing training"
}
|
B
|
[
"NCT00741832",
"NCT00037973",
"NCT00711438",
"NCT01223807"
] | 484 |
train
|
NCT00038480
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Study of Lopinavir/Ritonavir in HIV-1 Infected Infants Less Than 6 Months of Age
Brief Summary: The purpose of this study is to find out if the drug lopinavir/ritonavir (LPV/RTV) is safe and well tolerated in HIV infected infants. This study will also determine the most effective dose of LPV/RTV for infants.
|
{
"A": "Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): N/A",
"B": "Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abacavir, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nelfinavir, Drug: Nevirapine, Drug: Zidovudine | Intervention Type: DRUG; Name: Abacavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nelfinavir; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): 1, 2",
"C": "Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo",
"D": "Intervention Type: DRUG; Name: nevirapine; Assigned to Arm(s): N/A"
}
|
A
|
[
"NCT00038480",
"NCT00234091",
"NCT00197587",
"NCT00117728"
] | 485 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo",
"B": "Intervention Type: BEHAVIORAL; Name: obesity intervention; Assigned to Arm(s): N/A",
"C": "Arm Label: High intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Low intensity intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): High intensity intervention group, Low intensity intervention group",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Intensive Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle; Assigned to Arm(s): Intensive Lifestyle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00038727",
"NCT00435734",
"NCT00289237",
"NCT00004992"
] | 486 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Lipitor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lipitor; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo",
"C": "Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: SIMVASTATIN | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: SIMVASTATIN | Intervention Type: DRUG; Name: SIMVASTATIN; Assigned to Arm(s): A, B",
"D": "Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
B
|
[
"NCT00529542",
"NCT00038727",
"NCT00575601",
"NCT01072097"
] | 487 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): 2",
"B": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"C": "Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A",
"D": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo"
}
|
D
|
[
"NCT00724165",
"NCT00017953",
"NCT00435240",
"NCT00038727"
] | 488 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo",
"B": "Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"C": "Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes",
"D": "Arm Label: Pioglitazone; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00038727",
"NCT00091949",
"NCT01272219",
"NCT00708175"
] | 489 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo",
"B": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"C": "Intervention Type: DRUG; Name: Ramipril; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A",
"D": "Arm Label: Valsartan 160 mg + nateglinide 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide 60 mg | Arm Label: Valsartan 160 mg + nateglinide placebo; Type: EXPERIMENTAL; Interventions: Drug: Valsartan 160 mg + nateglinide placebo | Arm Label: Nateglinide 60 mg + valsartan placebo; Type: EXPERIMENTAL; Interventions: Drug: Nateglinide 60 mg + valsartan placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valsartan placebo + nateglinide placebo | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide 60 mg; Assigned to Arm(s): Valsartan 160 mg + nateglinide 60 mg | Intervention Type: DRUG; Name: Valsartan 160 mg + nateglinide placebo; Assigned to Arm(s): Valsartan 160 mg + nateglinide placebo | Intervention Type: DRUG; Name: Nateglinide 60 mg + valsartan placebo; Assigned to Arm(s): Nateglinide 60 mg + valsartan placebo | Intervention Type: DRUG; Name: Valsartan placebo + nateglinide placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00038727",
"NCT00220961",
"NCT00095654",
"NCT00097786"
] | 490 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo",
"C": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo",
"D": "Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: gastric banding; Type: EXPERIMENTAL; Interventions: Device: gastric banding | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DEVICE; Name: gastric banding; Assigned to Arm(s): gastric banding"
}
|
C
|
[
"NCT01557166",
"NCT00974272",
"NCT00038727",
"NCT01763346"
] | 491 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education",
"B": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE with pedometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PREPARE | Intervention Type: BEHAVIORAL; Name: PREPARE with pedometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: PREPARE; Assigned to Arm(s): 2",
"C": "Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Structured Education | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Written Information | Intervention Type: BEHAVIORAL; Name: Structured Education; Assigned to Arm(s): Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: Written Information; Assigned to Arm(s): Control",
"D": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo"
}
|
D
|
[
"NCT00017953",
"NCT00566319",
"NCT00941954",
"NCT00038727"
] | 492 |
train
|
NCT00038727
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Diabetes Prevention Program Outcomes Study
Brief Summary: The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 mg/dl). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%.
DPPOS (2002-2013) is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest at risk population ever studied. Clinically important research questions remain that focus on 1) durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding microvascular disease, CVD risk factors and atherosclerosis, 3) close examination of these topics in men vs women and in minority populations.
The major aims of DPPOS-3 (2014-2025) take advantage of the long-term randomized exposure of the study cohort to metformin and the aging of the DPPOS cohort. The metformin exposure and high degree of study retention and adherence (\~85% of the DPPOS cohort continues to attend annual and mid-year visits) allows DPPOS-3 to examine the long-term effects of metformin on cardiovascular disease (CVD) and cancer outcomes, outcomes of great clinical interest and import.
|
{
"A": "Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo",
"B": "Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride",
"C": "Arm Label: Liraglutid; Type: ACTIVE_COMPARATOR; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutid | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo",
"D": "Arm Label: 1 Original Lifestyle; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: DPPOS Boost Lifestyle, Behavioral: Intensive Lifestyle Group Session | Arm Label: 2 Original Metformin; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Drug: Metformin, Behavioral: Intensive Lifestyle Group Session | Arm Label: 3 Original Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: DPPOS Group Lifestyle, Behavioral: Intensive Lifestyle Group Session | Intervention Type: BEHAVIORAL; Name: DPPOS Group Lifestyle; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 2 Original Metformin | Intervention Type: BEHAVIORAL; Name: DPPOS Boost Lifestyle; Assigned to Arm(s): 1 Original Lifestyle | Intervention Type: BEHAVIORAL; Name: Intensive Lifestyle Group Session; Assigned to Arm(s): 1 Original Lifestyle, 2 Original Metformin, 3 Original Placebo"
}
|
D
|
[
"NCT00968708",
"NCT00622284",
"NCT01472640",
"NCT00038727"
] | 493 |
train
|
NCT00039988
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol
Brief Summary: The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).
MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
|
{
"A": "Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM",
"B": "Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: IFN-β-1a / 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon β-1a, Drug: Teriflunomide | Intervention Type: DRUG; Name: Interferon β-1a; Assigned to Arm(s): IFN-β-1a / 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): IFN-β-1a / 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1",
"D": "Arm Label: Double-blind Natalizumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Arm Label: Double-blind Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Open-label Natalizumab; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab (BG00002) | Intervention Type: DRUG; Name: Natalizumab (BG00002); Assigned to Arm(s): Double-blind Natalizumab 300 mg, Open-label Natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Double-blind Placebo"
}
|
C
|
[
"NCT01064401",
"NCT00883337",
"NCT00039988",
"NCT01440101"
] | 494 |
train
|
NCT00039988
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol
Brief Summary: The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).
MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
|
{
"A": "Arm Label: IFNB-1b 500 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: IFNB-1b 250 mcg*; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 500 mcg | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): IFNB-1b 250 mcg*",
"B": "Arm Label: Glatiramer acetate; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer Acetate (DB), Drug: Glatiramer Acetate (OL) | Arm Label: Placebo (DB) to GA (OL); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Glatiramer Acetate (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (DB); Assigned to Arm(s): Glatiramer acetate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo (DB) to GA (OL) | Intervention Type: DRUG; Name: Glatiramer Acetate (OL); Assigned to Arm(s): Glatiramer acetate, Placebo (DB) to GA (OL)",
"C": "Arm Label: Interferon beta 1-a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Other: placebo | Arm Label: glatiramer acetate; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate, Other: placebo | Arm Label: IFN and GA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta 1-a, Drug: glatiramer acetate | Intervention Type: DRUG; Name: Interferon beta 1-a; Assigned to Arm(s): IFN and GA, Interferon beta 1-a | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): IFN and GA, glatiramer acetate | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Interferon beta 1-a, glatiramer acetate",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1"
}
|
D
|
[
"NCT00459667",
"NCT00666224",
"NCT00211887",
"NCT00039988"
] | 495 |
train
|
NCT00039988
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol
Brief Summary: The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).
MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
|
{
"A": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1",
"B": "Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Biological: Alemtuzumab | Arm Label: Interferon Beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a | Intervention Type: BIOLOGICAL; Name: Alemtuzumab; Assigned to Arm(s): Alemtuzumab | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): Interferon Beta-1a",
"C": "Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): N/A",
"D": "Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo"
}
|
A
|
[
"NCT00039988",
"NCT00530348",
"NCT00168701",
"NCT00420212"
] | 496 |
train
|
NCT00039988
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol
Brief Summary: The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).
MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
|
{
"A": "Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A",
"B": "Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Ozanimod1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Interferon beta-1a placebo | Arm Label: Interferon β-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ozanimod placebo, Drug: Interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg | Intervention Type: DRUG; Name: Ozanimod placebo; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon β-1a | Intervention Type: DRUG; Name: Interferon beta-1a placebo; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod1 mg",
"C": "Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Arm Label: Dimethyl Fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl Fumarate | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700 | Intervention Type: DRUG; Name: Dimethyl Fumarate; Assigned to Arm(s): Dimethyl Fumarate",
"D": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1"
}
|
D
|
[
"NCT00109161",
"NCT02047734",
"NCT03093324",
"NCT00039988"
] | 497 |
train
|
NCT00039988
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Multiple Sclerosis With Copaxone (Glatiramer Acetate) and Albuterol
Brief Summary: The purpose of this study is to determine the effects of glatiramer acetate (Copaxone) alone compared to Copaxone plus albuterol in patients with Multiple Sclerosis (MS).
MS is thought to be an autoimmune disease of the central nervous system. Certain white blood cells of the immune system become abnormally active and mistakenly attack the myelin of nerve fibers. Myelin is a fatty sheath that surrounds nerve fibers and insulates the nerve like insulation around an electrical wire. Without proper myelin insulation, messages sent between the brain and other parts of the body may be confused or fail completely. Damage to myelin causes the symptoms of MS. The most common form of MS is known as relapsing-remitting (RR), where partial or total recovery occurs after attacks. Four therapies are currently approved for the treatment of MS. These therapies, however, are only moderately effective and can cause undesirable side effects. For this reason, there is a need to find new therapies that have minimal side effects and may stop the disease from getting worse.
|
{
"A": "Arm Label: Rebif®; Type: EXPERIMENTAL; Interventions: Drug: Rebif® | Arm Label: Copaxone®; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone® | Intervention Type: DRUG; Name: Rebif®; Assigned to Arm(s): Rebif® | Intervention Type: DRUG; Name: Copaxone®; Assigned to Arm(s): Copaxone®",
"B": "Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2",
"C": "Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1",
"D": "Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046) | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copaxone | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Interferon beta-1b (Betaferon/Betaseron, BAY86-5046); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Copaxone; Assigned to Arm(s): Arm 3"
}
|
C
|
[
"NCT00078338",
"NCT00027300",
"NCT00039988",
"NCT00099502"
] | 498 |
train
|
NCT00041054
|
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients With Extensive Small Cell Lung Cancer
Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy. Combining chemotherapy with exisulind may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with exisulind in treating patients who have extensive-stage small cell lung cancer.
|
{
"A": "Arm Label: Oxycodone Hydrochloride Tablets; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone | Arm Label: Oxycodone Naloxone Tablets; Type: EXPERIMENTAL; Interventions: Drug: Oxycodone/Naloxone | Intervention Type: DRUG; Name: Oxycodone; Assigned to Arm(s): Oxycodone Hydrochloride Tablets | Intervention Type: DRUG; Name: Oxycodone/Naloxone; Assigned to Arm(s): Oxycodone Naloxone Tablets",
"B": "Arm Label: carboplatin + etoposide + exisulind; Type: EXPERIMENTAL; Interventions: Drug: carboplatin, Drug: etoposide, Drug: exisulind | Intervention Type: DRUG; Name: carboplatin; Assigned to Arm(s): carboplatin + etoposide + exisulind | Intervention Type: DRUG; Name: etoposide; Assigned to Arm(s): carboplatin + etoposide + exisulind | Intervention Type: DRUG; Name: exisulind; Assigned to Arm(s): carboplatin + etoposide + exisulind",
"C": "Arm Label: The LCP-I Program.; Type: EXPERIMENTAL; Interventions: Other: The LCP-I Program | Arm Label: standard healthcare practices; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: The LCP-I Program; Assigned to Arm(s): The LCP-I Program.",
"D": "Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: R331333 (referred to as JNS024 ER or CG5503) | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxycodone CR | Intervention Type: DRUG; Name: Oxycodone CR; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: R331333 (referred to as JNS024 ER or CG5503); Assigned to Arm(s): 001"
}
|
B
|
[
"NCT00513656",
"NCT00041054",
"NCT01081899",
"NCT01165281"
] | 499 |
train
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.